Cases Presented With Fluidx GPX Embolic Device to Treat Arterial and Venous Tumor

February 2, 2021—Fluidx Medical Technology announced that the first patient-use cases with the company’s GPX embolic device were presented by Andrew Holden, MD, at LINC 2021, the Leipzig Interventional Course held January 25-29.

According to the company, the GPX embolic device is designed to combine the benefits of other embolics such as coils, particles, and liquids with simplified preparation, delivery, precision, and control leading to durable, long-term occlusions. The GPX technology is a low-viscosity, aqueous-based solution in a syringe that solidifies into a durable embolic material on delivery, without polymerization or dimethyl-sulfoxide precipitation associated with other embolics. The GPX embolic device is not available for sale in the United States or other markets and is for investigational use only, advised the company.

Dr. Holden, who is Director of Interventional Radiology at Auckland City Hospital in Auckland, New Zealand, commented in the Fluidx press release, “This is very promising technology. The very radiopaque GPX penetrates distally extremely well with excellent control and devascularized the renal tumor entirely.”

In the LINC 2021 presentation, Dr. Holden showed cases in which GPX had successfully embolized the arterial vasculature of a renal angiomyolipoma and in another case, portal vein embolization in a patient with metastatic colon cancer. Of the latter case, Dr. Holden said the successful procedure “resulted in complete occlusion of the portal vein branches and excellent visualization of the target site. At the 6-week CT scan, we can see the branch impact of the occlusion, and the patient experienced good left lobe hypertrophy.”